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(First published online 10 October 2008)
The response by Brewer & Althaus to our recent review on
biomarkers for Cu(1) bears testimony that the subject is topical
and of public, scientific and commercial interest. It is valuable
that a private company like Pipex Pharmaceuticals, Inc. is now
interested in an area that was long thought to be peripheral to
human health.
We acknowledge that there is disagreement regarding the
prevalence of Cu deficiency and the use of ceruloplasmin
(Cp) as a marker for marginal Cu status. This currently
cannot be resolved.
Brewer & Althaus note that many symptoms of Cu
deficiency cited by us are observed in animal models, and
not in humans. This is a weakness inherent to fundamental
scientific research, and the authors (Brewer & Althaus)
must be aware that they base their own arguments regarding
the role of Cu in Alzheimer’s disease (AD) on no fewer
than eleven animal studies. In addition, all cited studies
showing a negative effect of Cu on the progression of AD
are carried out in rabbits fed extremely high cholesterol
levels in the diet, or in animals that are spontaneously
hypercholesterolaemic. This rather artificial animal model is
cited with surprising confidence by Brewer & Althaus in
three instances.
There is no evidence to support the statement that ‘copper
in drinking water and copper in supplements [. . .] bypasses
the liver for a time and is available to directly penetrate the
blood brain barrier.’ In contrast, Cu is thought to be taken
up into the brain by ATP7A or Ctr1 in a controlled manner
(see, for example, Nishihara et al. (2) and Kuo et al. (3)).
We strongly feel that the term ‘free Cu’ is inappropriate, as
it has long ago been demonstrated that ‘free Cu’ is extremely
unlikely to exist in biological systems. It is too reactive, and
will be bound to proteins or amino acids immediately. We
refer to a classic paper by O’Halloran et al., which appeared
in 1999 in the journal Science (4). Brewer and colleagues use
the term ‘free Cu’ to describe ‘non-Cp-bound Cu’, and we
suggest that the more accurate term be used.
Ultimately, however, there may be less disagreement
between us and Brewer & Althaus, as we refer to a recent
publication by Brewer(5): in this paper, Cp is mentioned as
an acute-phase reactant (especially in atherosclerosis) and as
a marker of inflammation, which in our view limits its useful-
ness as a biomarker for Cu. Brewer also correctly discusses
that there is significant controversy over the role of Cu in
the pathogenesis of AD. He mentions animal studies in
which an increase in brain Cu due to a mutant ATP7B Cu
transporter resulted in a reduction of Ab in the brain(6), sup-
plementation with Cu in an AD mouse model which lowered
Ab production and increased longevity(7), and human AD
studies in which cognitive decline correlated positively with
low plasma levels of Cu(8). We agree with Brewer’s fair
assessment of this controversial issue.
Brewer further underlines the importance of Cu on page
327 of the same paper(5): ‘Deficiency leads to anemia and
bone marrow suppression, followed by a neurologic syn-
drome called a myelopathy. . . the most bioavailable source
of copper is in meat. [. . .] vegetarian diets are much
more borderline in providing adequate copper. . .’ And on
page 328: ‘It is clear, of course, that copper levels must not
be lowered into the range where the activities of copper-depen-
dent enzymes are affected, because that adversely affects the
vasculature.’ Again, we are in agreement with Brewer’s
comments.
Brewer & Althaus heavily rely on the recently published
data by the Italian group including Squitti and Rossini as ulti-
mate ‘proof of concept’ of elevated ‘free Cu’ in AD. Again,
we do not disagree with those studies, and instead commend
the careful discussion and caution employed by Squitti et al.
in interpretation of their own data. This may reflect the fact
that some of their studies have used highly sophisticated stat-
istics to show what was not conclusive from the experiments.
‘Non-ceruloplasmin bound copper (‘free’) seems slightly
elevated in AD patients.’ ‘The reliability of copper as a
marker of AD has yet to be proven and the debate on the
toxic or protective role of this metal in AD is still ongoing.’
‘Evidence of ‘free’ copper in AD is still scanty,. . .’ ‘The
data collected at this stage of the research are surely not suf-
ficient to draw conclusions about the effective implication
of copper in AD.’ These are all direct citations from
Squitti et al. (9).
It is curious that Brewer & Althaus use the data described
above for extrapolation not only to the development of a
device called FreeBound to measure ‘free Cu’, but also to
the use of a chelator (tetrathiomolybdate) binding ‘free Cu’.
The latter product is called COPREXA, and several press
releases by Pipex in late 2007 have announced the testing of
this product in pre-clinical and clinical AD studies.
The concept of Cu chelation in AD is not new, and has been
thoroughly explored by Prana Biotechnology, a company
based in Australia. After the first compound Clioquinol, a
Cu chelator, failed in clinical trials, Prana’s scientific co-foun-
der is now publishing statements such as ‘Based upon our cur-
rent findings, to normalize brain metal levels in AD, a drug
would need to increase copper levels and decrease zinc
levels while preventing pooling of these metal ions in the
amyloid mass.’(10)
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We want to stress that the role of Cu in AD and many other
diseases remains controversial, and that there is not enough
data to justify the use of Cu chelation in AD. A Cu chelator
cannot be expected to solve problems as diverse as AD,
macular degeneration and fibrotic disease, as advertised by
Pipex. While Cu can be toxic when present in excess, it is
an essential nutrient. The ‘removal’ of any essential nutrient,
including Cu, must be viewed with caution.
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